Medexus Historical Income Statement
| MDP Stock | 2.74 0.07 2.49% |
Historical analysis of Medexus Pharmaceuticals income statement accounts such as Ebitda of 22.5 M can show how well Medexus Pharmaceuticals performed in making a profits. Evaluating Medexus Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Medexus Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Medexus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Medexus Pharmaceuticals is a good buy for the upcoming year.
Medexus |
About Medexus Income Statement Analysis
Medexus Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Medexus Pharmaceuticals shareholders. The income statement also shows Medexus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Medexus Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Medexus Pharmaceuticals. It is also known as Medexus Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Medexus Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Medexus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medexus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Medexus Pharmaceuticals' Net Income is very stable compared to the past year. As of the 22nd of July 2025, Total Revenue is likely to grow to about 113.7 M, while Selling And Marketing Expenses is likely to drop about 9.3 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Gross Profit | 60.0M | 59.5M | 56.6M | 28.9M | Total Revenue | 108.1M | 113.1M | 108.3M | 113.7M |
Medexus Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Medexus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Medexus Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Selling General Administrative | 19.3M | 34.5M | 36.9M | 27.9M | 43.2M | 45.3M | |
| Other Operating Expenses | 78.9M | 89.1M | 99.6M | 100.3M | 115.3M | 121.1M | |
| Operating Income | (1.4M) | (15.0M) | 7.6M | 10.8M | 8.2M | 8.6M | |
| Ebitda | 6.7M | (6.2M) | 14.6M | 18.6M | 21.4M | 22.5M | |
| Total Operating Expenses | 41.3M | 50.3M | 51.5M | 46.7M | 96.4M | 101.2M | |
| Income Before Tax | (31.5M) | (3.8M) | (5.0M) | 106K | 1.4M | 1.5M | |
| Net Income | (28.3M) | (2.9M) | 1.2M | (214K) | 2.2M | 2.4M | |
| Selling And Marketing Expenses | 16.9M | 9.5M | 11.4M | 10.6M | 12.2M | 9.3M | |
| Total Revenue | 79.7M | 76.7M | 108.1M | 113.1M | 108.3M | 113.7M | |
| Gross Profit | 42.0M | 37.9M | 60.0M | 59.5M | 56.6M | 28.9M | |
| Research Development | 4.6M | 5.9M | 2.9M | 8.0M | 8.3M | 4.5M | |
| Total Other Income Expense Net | (22.4M) | 20.8M | 76K | 683K | (2.3M) | (2.2M) | |
| Depreciation And Amortization | 7.9M | 7.7M | 8.0M | 7.8M | 9.0M | 9.5M | |
| Interest Expense | 9.8M | 12.2M | 13.6M | 13.4M | 8.2M | 6.9M | |
| Ebit | (1.2M) | (13.9M) | 6.5M | 10.8M | 12.4M | 13.0M | |
| Income Tax Expense | (3.2M) | (941K) | (6.3M) | 320K | 288K | 302.4K | |
| Cost Of Revenue | 37.7M | 38.8M | 48.1M | 53.5M | 51.7M | 29.7M | |
| Interest Income | 3K | 11.2M | 12.7M | 10.7M | 6.8M | 5.2M | |
| Net Income Applicable To Common Shares | (28.3M) | (2.9M) | 1.2M | (214K) | 2.2M | 2.4M | |
| Net Interest Income | (9.8M) | (12.2M) | (13.6M) | (13.4M) | (8.2M) | (8.6M) | |
| Net Income From Continuing Ops | (28.3M) | (2.9M) | 1.2M | (214K) | 2.2M | 2.4M | |
| Reconciled Depreciation | 6.0M | 6.1M | 6.1M | 5.8M | 7.2M | 5.1M | |
| Tax Provision | (3.2M) | (941K) | (6.3M) | 320K | (807K) | (847.4K) |
Pair Trading with Medexus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Medexus Stock
Moving against Medexus Stock
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Medexus Pharmaceuticals shareholders. The income statement also shows Medexus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).